Vasopharm GmbH, a privately held German company focused on cerebrovascular diseases, has raised €20 million from venture capital companies to finance Phase 3 development of its lead product for traumatic brain injury VAS203. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
